港股異動 | 今日起摘“B” 榮昌生物尾盤升幅擴大至超10%
格隆匯6月14日丨榮昌生物(9995.HK)尾盤升幅擴大至超10%,現報34.45港元,成交額放大至9781萬港元,總市值187億港元。公司昨晚公吿,自2023年6月14日起,公司的股份簡稱將不再加上標記“B”。此次摘“B”,意味着榮昌生物在市值和收入等方面達到了更高標準,是公司發展史上的又一里程碑。目前,公司核心產品泰它西普(泰愛)、維迪西妥單抗(愛地希)已於2021年在國內獲批上市並雙雙納入國家醫保藥品目錄,市場銷售放量明顯,彰顯了巨大的臨牀價值和商業價值。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.